Life Sci Acquisition

LifeSci Acquisition Corporation, a Special Purpose Acquisition Company, Sponsored by an Affiliate of LifeSci Partners, Announces the Acquisition of Vincera Pharma

LifeSci Acquisition Corp. (Nasdaq: LSAC, LSACU AND LSACW) is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities, pursuing targets that are focused on healthcare innovation in North America or Europe.

View Our Prospectus

Management Team

Andrew McDonald
Chief Executive Officer

Andrew McDonald

Chief Executive Officer 

Andrew is an experienced healthcare investment professional with expertise identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Advisors and LifeSci Captial. Prior to founding LifeSci, Andrew serves as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004 – 2006 Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001 – 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at U.C. Berkley. Andrew holds the Series 7, 24, 63, 79, 86, and 87.

Michael Rice
Chief Operating Officer

Michael Rice

Chief Operating Officer
Michael has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
David Dobkin
Chief Financial Officer

David Dobkin

Chief Financial Officer

David is an experienced healthcare capital markets investment banker with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. Prior to joining LifeSci Capital, David founded Dobkin & Company, an investment bank tailored for entrepreneur-lead companies focused on seed and growth equity and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October 2010, David worked for Lazard Frères, one of the world’s preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers and acquisitions transactions in excess of $3 billion. Prior to joining for Lazard Frères, David began his career in in the Healthcare investment banking group for Wasserstein Perella based in New York. David conducted graduate research in stem cell bio-engineering and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a Bachelor of Science, Biomedical Engineering, from Columbia University. David holds the Series 63, 79, and 82.

Matthew Margiotta
Vice President

Matthew Margiotta

Vice President

Matthew joined LifeSci Capital in 2018 as a member of the investment banking team, where he has advised on capital markets and M&A transactions for promising early-stage biotech and medtech, behavioral health, and healthcare technology companies. Prior to joining LifeSci, Matthew spent time at Bank of America Merrill Lynch and UBS in their Global Wealth & Investment Management divisions, with a focus on biotech equity research. Matthew graduated from the University of Michigan and received his B.S. with majors in Mathematics and Statistics. 

Bob Spivak
Vice President

Bob Spivak

Vice President

Bob joined LifeSci Capital in 2018 as a member of the investment banking team, where he advises on both capital markets and M&A transactions for biotech, medtech, healthcare services and healthcare technology companies. Bob is also the Vice President of LifeSci Acquisition and LifeSci Acquisition II, where he assists in identifying a strong target to acquire into LifeSci’s special purpose acquisition company. Prior to joining LifeSci, Bob spent his time at Maxim Group in their investment banking division. Bob graduated from Pace University and received a BBA with majors in Finance and Mathematics.

Board of Directors

• Brian Schwartz, M.D.

Brian Schwartz

Previously served as Chief Medical Officer at ArQule, Inc., a biotechnology company, since June 2008. Previously, he served as Senior Vice President, clinical and regulatory affairs, and Chief Medical Officer Ziopharm Oncology, Inc. Prior to Ziopharm, Dr. Schwartz held a number of positions at Bayer Healthcare. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of Nexavar® (sorafenib) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to FDA approval. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry.

• Barry Dennis

Barry Dennis

Managing Director of Investment Banking and Strategic Consulting at WaveCrest Securities. Prior to joining WaveCrest, Barry served as President of Strategos Capital Markets, a structured products hedge fund. Barry also worked for Canaccord Genuity, Merrill Lynch, TD Securities, and BMO. Barry received his Bachelor’s of Commerce from the University of British Columbia and his M.B.A from the University of Western Ontario.

• John Ziegler, M.D.

John Ziegler, M.D.

John has over 30 years of clinical practice as an anesthesiologist with a career focus on pain management, cardiac anesthesia and critical care medicine. He is triple board certified as an anesthesiologist, critical care physician and echocardiographer. He also has extensive experience in the administrative and operational aspects of clinical research and drug development. Dr. Ziegler has been involved in clinical research oversight for most of his medical career. John received his Doctor of Medicine from Emory University School of Medicine, where he also completed his residency and fellowships.

• Jonas Grossman

Jonas Grossman

President of Chardan Capital Markets, where he oversees the firm’s global capital markets initiatives including healthcare investment banking and the sponsorship by Chardan affiliates of 5 SPACs, all of which concluded their business combinations. Jonas was the Chief Executive Officer and President of the SPAC Chardan Healthcare Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX, Ltd. (NYSE: PHGE). Jonas is currently a director of BiomX. Prior to joining Chardan, Jonas was a Vice President and Head Trader at Ramius Capital Group, a global multi-strategy hedge fund. Jonas received his B.A. in Economics from Cornell University and his M.B.A. from the Stern School of Business at NYU.

• Karin Walker 

Karin Walker

Chief Accounting Officer and Controller of Prothena (NASDAQ:PRTA), a clinical stage biotech company focused on amyloid and inflammatory diseases. Prior to joining Prothena, Karin served as VP of Finance and Chief Accounting Officer at Affymax, as well as VP of Finance at Amyris and CV Therapeutics. Karin began her career at EY as an accountant, and received her B.S. in Finance at California State Polytechnic University, San Luis Obispo.

About Vincera

Vincera is a recently formed clinical-stage biopharmaceutical company leveraging its extensive development and oncology expertise to advance new therapies to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincera’s management team of biopharmaceutical experts has an industry-leading track record of discovering and developing blockbuster oncology drugs.

Vincera’s current pipeline is derived from an exclusive option to license agreement with Bayer for an oncology portfolio which includes (i) a clinical-stage small molecule PTEFb/CDK9 inhibitor with a follow-on oral program and (ii) a preclinical next-generation bioconjugation platform to overcome the limitations of antibody and small molecule drug conjugates. The company intends to leverage strong partnerships to develop multiple products with the potential for accelerated approvals through clinical proof-of-concept.

To learn more about Vincera, please visit https://vincerapharma.com/

Press Release

LifeSci Acquisition Corp. Announces Merger Agreement with Vincera Pharma, Inc. to Create New Publicly Listed Oncology Company

Presentations

Corporate Overview

Investors

NASDAQ: VINC

SEC PROSPECTUS (424B4)
© 2020 LifeSci Acquisition Corp. All rights reserved.    Privacy Policy
Life Sci Acquisition